Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Research

The French National Registry of patients with Facioscapulohumeral muscular dystrophy

Authors: Céline Guien, Gaëlle Blandin, Pauline Lahaut, Benoît Sanson, Katia Nehal, Sitraka Rabarimeriarijaona, Rafaëlle Bernard, Nicolas Lévy, Sabrina Sacconi, Christophe Béroud

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Facioscapulohumeral muscular dystrophy is a rare inherited neuromuscular disease with an estimated prevalence of 1/20,000 and France therefore harbors about 3000 FSHD patients. With research progress and the development of targeted therapies, patients’ identification through registries can facilitate and improve recruitment in clinical trials and studies.

Results

The French National Registry of FSHD patients was designed as a mixed model registry involving both patients and physicians, through self-report and clinical evaluation questionnaires respectively, to collect molecular and clinical data. Because of the limited number of patients, data quality is a major goal of the registry and various automatic data control features have been implemented in the bioinformatics system. In parallel, data are manually validated by molecular and clinical curators. Since its creation in 2013, data from 638 FSHD patients have been collected, representing about 21% of the French FSHD population. The mixed model strategy allowed to collect 59.1% of data from both patients and clinicians; 26 and 14.9% from respectively patients and clinicians only. With the identification of the FSHD1 and FSHD2 forms, specific questionnaires have been designed. Though FSHD2 patients are progressively included, FSHD1 patients still account for the majority (94.9%). The registry is compatible with the FAIR principles as data are Findable, Accessible and Interoperable. We thus used molecular standards and standardized clinical terms used by the FILNEMUS French network of reference centers for the diagnosis and follow-up of patients suffering from a rare neuromuscular disease. The implemented clinical terms mostly map to dictionaries and terminology systems such as SNOMED-CT (75% of terms), CTV3 (61.7%) and NCIt (53.3%). Because of the sensitive nature of data, they are not directly reusable and can only be accessed as aggregated data after evaluation and approval by the registry oversight committee.

Conclusions

The French National Registry of FSHD patients belongs to a national effort to develop databases, which should now interact with other initiatives to build a European and/or an international FSHD virtual registry for the benefits of patients. It is accessible at www.​fshd.​fr and various useful information, links, and documents, including a video, are available for patients and professionals.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mostacciuolo ML, Pastorello E, Vazza G, Miorin M, Angelini C, Tomelleri G, et al. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet Blackwell Publishing Ltd. 2009;75:550–5. Mostacciuolo ML, Pastorello E, Vazza G, Miorin M, Angelini C, Tomelleri G, et al. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet Blackwell Publishing Ltd. 2009;75:550–5.
2.
go back to reference Deenen JCW, Arnts H, van der Maarel SM, Padberg GW, Verschuuren JJGM, Bakker E, et al. Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology. 2014;83:1056–9.CrossRefPubMedPubMedCentral Deenen JCW, Arnts H, van der Maarel SM, Padberg GW, Verschuuren JJGM, Bakker E, et al. Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology. 2014;83:1056–9.CrossRefPubMedPubMedCentral
3.
go back to reference Sacconi S, Salviati L, Desnuelle C. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta. 1852;2015:607–14. Sacconi S, Salviati L, Desnuelle C. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta. 1852;2015:607–14.
4.
go back to reference Statland JM, Tawil R. Risk of functional impairment in Facioscapulohumeral muscular dystrophy. Muscle Nerve. 2014;49:520–7.CrossRefPubMed Statland JM, Tawil R. Risk of functional impairment in Facioscapulohumeral muscular dystrophy. Muscle Nerve. 2014;49:520–7.CrossRefPubMed
5.
go back to reference Goselink RJM, Voermans NC, Okkersen K, OF B, Padberg GW, Nikolic A, et al. Early onset facioscapulohumeral dystrophy - a systematic review using individual patient data. Neuromuscul Disord. 2017;27:1077–83.CrossRefPubMed Goselink RJM, Voermans NC, Okkersen K, OF B, Padberg GW, Nikolic A, et al. Early onset facioscapulohumeral dystrophy - a systematic review using individual patient data. Neuromuscul Disord. 2017;27:1077–83.CrossRefPubMed
6.
go back to reference Moreira S, Wood L, Smith D, Marini-Bettolo C, Guglieri M, McMacken G, et al. Respiratory involvement in ambulant and non-ambulant patients with facioscapulohumeral muscular dystrophy. J Neurol. 2017;264:1271–80.CrossRefPubMedPubMedCentral Moreira S, Wood L, Smith D, Marini-Bettolo C, Guglieri M, McMacken G, et al. Respiratory involvement in ambulant and non-ambulant patients with facioscapulohumeral muscular dystrophy. J Neurol. 2017;264:1271–80.CrossRefPubMedPubMedCentral
7.
go back to reference Trevisan CP, Pastorello E, Armani M, Angelini C, Nante G, Tomelleri G, et al. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. Eur Neurol. 2006;56:1–5.CrossRefPubMed Trevisan CP, Pastorello E, Armani M, Angelini C, Nante G, Tomelleri G, et al. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. Eur Neurol. 2006;56:1–5.CrossRefPubMed
8.
go back to reference Padberg GW, OF B, de Keizer RJ, Dijkman G, Wijmenga C, Grote JJ, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve Suppl. 1995;2:S73–80.CrossRefPubMed Padberg GW, OF B, de Keizer RJ, Dijkman G, Wijmenga C, Grote JJ, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve Suppl. 1995;2:S73–80.CrossRefPubMed
9.
go back to reference Cooper D, Upadhhyaya M. Facioscapulohumeral Muscular Dystrophy (FSHD). Garland Sci. 2004. Cooper D, Upadhhyaya M. Facioscapulohumeral Muscular Dystrophy (FSHD). Garland Sci. 2004.
10.
go back to reference Trevisan CP, Pastorello E, Ermani M, Angelini C, Tomelleri G, Tonin P, et al. Facioscapulohumeral muscular dystrophy: a multicenter study on hearing function. Audiol Neurootol. 2008;13:1–6.CrossRefPubMed Trevisan CP, Pastorello E, Ermani M, Angelini C, Tomelleri G, Tonin P, et al. Facioscapulohumeral muscular dystrophy: a multicenter study on hearing function. Audiol Neurootol. 2008;13:1–6.CrossRefPubMed
11.
go back to reference Lutz KL, Holte L, Kliethermes SA, Stephan C, Mathews KD. Clinical and genetic features of hearing loss in facioscapulohumeral muscular dystrophy. Neurology. 2013;81:1374–7.CrossRefPubMedPubMedCentral Lutz KL, Holte L, Kliethermes SA, Stephan C, Mathews KD. Clinical and genetic features of hearing loss in facioscapulohumeral muscular dystrophy. Neurology. 2013;81:1374–7.CrossRefPubMedPubMedCentral
12.
13.
go back to reference Statland JM, Sacconi S, Farmakidis C, Donlin-Smith CM, Chung M, Tawil R. Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size. Neurology. 2013;80:1247–50.CrossRefPubMedPubMedCentral Statland JM, Sacconi S, Farmakidis C, Donlin-Smith CM, Chung M, Tawil R. Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size. Neurology. 2013;80:1247–50.CrossRefPubMedPubMedCentral
14.
go back to reference Fitzsimons RB. Retinal vascular disease and the pathogenesis of facioscapulohumeral muscular dystrophy. A signalling message from Wnt? Neuromuscul Disord. 2011;21:263–71.CrossRefPubMed Fitzsimons RB. Retinal vascular disease and the pathogenesis of facioscapulohumeral muscular dystrophy. A signalling message from Wnt? Neuromuscul Disord. 2011;21:263–71.CrossRefPubMed
15.
go back to reference Wohlgemuth M, de Swart BJM, Kalf JG, Joosten FBM, Van der Vliet AM, Padberg GW. Dysphagia in facioscapulohumeral muscular dystrophy. Neurology. 2006;66:1926–8.CrossRefPubMed Wohlgemuth M, de Swart BJM, Kalf JG, Joosten FBM, Van der Vliet AM, Padberg GW. Dysphagia in facioscapulohumeral muscular dystrophy. Neurology. 2006;66:1926–8.CrossRefPubMed
16.
go back to reference Chen T-H, Lai Y-H, Lee P-L, Hsu J-H, Goto K, Hayashi YK, et al. Infantile facioscapulohumeral muscular dystrophy revisited: expansion of clinical phenotypes in patients with a very short EcoRI fragment. Neuromuscul Disord. 2013;23:298–305.CrossRefPubMed Chen T-H, Lai Y-H, Lee P-L, Hsu J-H, Goto K, Hayashi YK, et al. Infantile facioscapulohumeral muscular dystrophy revisited: expansion of clinical phenotypes in patients with a very short EcoRI fragment. Neuromuscul Disord. 2013;23:298–305.CrossRefPubMed
17.
go back to reference Padua L, Aprile I, Frusciante R, Iannaccone E, Rossi M, Renna R, et al. Quality of life and pain in patients with facioscapulohumeral muscular dystrophy. Muscle Nerve. 2009;40:200–5.CrossRefPubMed Padua L, Aprile I, Frusciante R, Iannaccone E, Rossi M, Renna R, et al. Quality of life and pain in patients with facioscapulohumeral muscular dystrophy. Muscle Nerve. 2009;40:200–5.CrossRefPubMed
18.
go back to reference Kalkman JS, Zwarts MJ, Schillings ML, van Engelen BGM, Bleijenberg G. Different types of fatigue in patients with facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I. Experienced fatigue and physiological fatigue. Neurol Sci. 2008;29(Suppl 2):S238–40.CrossRefPubMed Kalkman JS, Zwarts MJ, Schillings ML, van Engelen BGM, Bleijenberg G. Different types of fatigue in patients with facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I. Experienced fatigue and physiological fatigue. Neurol Sci. 2008;29(Suppl 2):S238–40.CrossRefPubMed
20.
go back to reference Zatz M, Marie SK, Cerqueira A, Vainzof M, Pavanello RCM, Passos Bueno MR. The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females. Am J Med Genet. 1998;77:155–61.CrossRefPubMed Zatz M, Marie SK, Cerqueira A, Vainzof M, Pavanello RCM, Passos Bueno MR. The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females. Am J Med Genet. 1998;77:155–61.CrossRefPubMed
21.
go back to reference van den Boogaard ML, Lemmers RJLF, Balog J, Wohlgemuth M, Auranen M, Mitsuhashi S, et al. Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of Facioscapulohumeral dystrophy. Am J Hum Genet. 2016;98:1020–9.CrossRefPubMedPubMedCentral van den Boogaard ML, Lemmers RJLF, Balog J, Wohlgemuth M, Auranen M, Mitsuhashi S, et al. Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of Facioscapulohumeral dystrophy. Am J Hum Genet. 2016;98:1020–9.CrossRefPubMedPubMedCentral
22.
go back to reference Evangelista T, Wood L, Fernandez-Torron R, Williams M, Smith D, Lunt P, et al. Design, set-up and utility of the UK facioscapulohumeral muscular dystrophy patient registry. J Neurol. 2016;263:1401–8.CrossRefPubMedPubMedCentral Evangelista T, Wood L, Fernandez-Torron R, Williams M, Smith D, Lunt P, et al. Design, set-up and utility of the UK facioscapulohumeral muscular dystrophy patient registry. J Neurol. 2016;263:1401–8.CrossRefPubMedPubMedCentral
23.
go back to reference Nikolic A, Ricci G, Sera F, Bucci E, Govi M, Mele F, et al. Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 1-3 D4Z4 reduced alleles: experience of the FSHD Italian National Registry. BMJ Open. 2016;6:e007798.CrossRefPubMedPubMedCentral Nikolic A, Ricci G, Sera F, Bucci E, Govi M, Mele F, et al. Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 1-3 D4Z4 reduced alleles: experience of the FSHD Italian National Registry. BMJ Open. 2016;6:e007798.CrossRefPubMedPubMedCentral
24.
go back to reference Hilbert JE, Kissel JT, Luebbe EA, Martens WB, McDermott MP, Sanders DB, et al. If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of myotonic dystrophy (DM) and Facioscapulohumeral muscular dystrophy (FSHD). Contemp Clin Trials. 2012;33:302–11.CrossRefPubMed Hilbert JE, Kissel JT, Luebbe EA, Martens WB, McDermott MP, Sanders DB, et al. If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of myotonic dystrophy (DM) and Facioscapulohumeral muscular dystrophy (FSHD). Contemp Clin Trials. 2012;33:302–11.CrossRefPubMed
25.
go back to reference Wei Y, McCormick A, MacKenzie A, O’Ferrall E, Venance S, Mah JK, et al. The Canadian neuromuscular disease registry: connecting patients to national and international research opportunities. Paediatr Child Health. 2018;23:20–6.CrossRefPubMed Wei Y, McCormick A, MacKenzie A, O’Ferrall E, Venance S, Mah JK, et al. The Canadian neuromuscular disease registry: connecting patients to national and international research opportunities. Paediatr Child Health. 2018;23:20–6.CrossRefPubMed
26.
go back to reference Mul K, Kinoshita J, Dawkins H, van Engelen B, Tupler R, FSHD Consortium. 225th ENMC international workshop:: A global FSHD registry framework, 18–20 November 2016, Heemskerk, The Netherlands. Neuromuscul Disord. 2017;27:782–90.CrossRefPubMed Mul K, Kinoshita J, Dawkins H, van Engelen B, Tupler R, FSHD Consortium. 225th ENMC international workshop:: A global FSHD registry framework, 18–20 November 2016, Heemskerk, The Netherlands. Neuromuscul Disord. 2017;27:782–90.CrossRefPubMed
27.
go back to reference Goselink RJM, Schreuder THA, Mul K, Voermans NC, Pelsma M, de Groot IJM, et al. Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD). BMC Neurol. 2016;16:138.CrossRefPubMedPubMedCentral Goselink RJM, Schreuder THA, Mul K, Voermans NC, Pelsma M, de Groot IJM, et al. Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD). BMC Neurol. 2016;16:138.CrossRefPubMedPubMedCentral
28.
go back to reference Statland JM, Donlin-Smith CM, Tapscott SJ, Lemmers RJLF, van der Maarel SM, Tawil R. Milder phenotype in facioscapulohumeral dystrophy with 7-10 residual D4Z4 repeats. Neurology. 2015;85:2147–50.CrossRefPubMedPubMedCentral Statland JM, Donlin-Smith CM, Tapscott SJ, Lemmers RJLF, van der Maarel SM, Tawil R. Milder phenotype in facioscapulohumeral dystrophy with 7-10 residual D4Z4 repeats. Neurology. 2015;85:2147–50.CrossRefPubMedPubMedCentral
29.
go back to reference Wood L, Cordts I, Atalaia A, Marini-Bettolo C, Maddison P, Phillips M, et al. The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research. J Neurol. 2017;264:979–88.CrossRefPubMedPubMedCentral Wood L, Cordts I, Atalaia A, Marini-Bettolo C, Maddison P, Phillips M, et al. The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research. J Neurol. 2017;264:979–88.CrossRefPubMedPubMedCentral
30.
go back to reference Statland JM, Tawil R. Facioscapulohumeral Muscular Dystrophy. Continuum (Minneap Minn). 2016;22:1916–31. Statland JM, Tawil R. Facioscapulohumeral Muscular Dystrophy. Continuum (Minneap Minn). 2016;22:1916–31.
31.
go back to reference Philippakis AA, Azzariti DR, Beltran S, Brookes AJ, Brownstein CA, Brudno M, et al. The matchmaker exchange: a platform for rare disease gene discovery. Hum Mutat. 2015;36:915–21.CrossRefPubMedPubMedCentral Philippakis AA, Azzariti DR, Beltran S, Brookes AJ, Brownstein CA, Brudno M, et al. The matchmaker exchange: a platform for rare disease gene discovery. Hum Mutat. 2015;36:915–21.CrossRefPubMedPubMedCentral
32.
go back to reference Via A, Attwood TK, Fernandes PL, Morgan SL, Schneider MV, Palagi PM, et al. A new pan-European Train-the-Trainer programme for bioinformatics: pilot results on feasibility, utility and sustainability of learning. Brief Bioinform. 2017;520:151. Via A, Attwood TK, Fernandes PL, Morgan SL, Schneider MV, Palagi PM, et al. A new pan-European Train-the-Trainer programme for bioinformatics: pilot results on feasibility, utility and sustainability of learning. Brief Bioinform. 2017;520:151.
33.
go back to reference Cutillo CM, Austin CP, Groft SC. A global approach to rare diseases research and orphan products development: the international rare diseases research consortium (IRDiRC). Adv Exp Med Biol. 2017;1031:349–69.CrossRefPubMed Cutillo CM, Austin CP, Groft SC. A global approach to rare diseases research and orphan products development: the international rare diseases research consortium (IRDiRC). Adv Exp Med Biol. 2017;1031:349–69.CrossRefPubMed
Metadata
Title
The French National Registry of patients with Facioscapulohumeral muscular dystrophy
Authors
Céline Guien
Gaëlle Blandin
Pauline Lahaut
Benoît Sanson
Katia Nehal
Sitraka Rabarimeriarijaona
Rafaëlle Bernard
Nicolas Lévy
Sabrina Sacconi
Christophe Béroud
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0960-x

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue